200 related articles for article (PubMed ID: 34842443)
1. Inhibition of SGLT1 Alleviates the Glycemic Variability-Induced Cardiac Fibrosis via Inhibition of Activation of Macrophage and Cardiac Fibroblasts.
Wu W; Chai Q; Zhang Z
Mol Cell Biol; 2022 Feb; 42(2):e0028221. PubMed ID: 34842443
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of SGLT1 protects against glycemic variability-induced cardiac damage and pyroptosis of cardiomyocytes in diabetic mice.
Sun Z; Chai Q; Zhang Z; Lu D; Meng Z; Wu W
Life Sci; 2021 Apr; 271():119116. PubMed ID: 33508297
[TBL] [Abstract][Full Text] [Related]
3. Glucose fluctuation accelerates cardiac injury of diabetic mice via sodium-dependent glucose cotransporter 1 (SGLT1).
Wu W; Chai Q; Zhang Z
Arch Biochem Biophys; 2021 Sep; 709():108968. PubMed ID: 34153296
[TBL] [Abstract][Full Text] [Related]
4. Intermittent high glucose induces pyroptosis of rat H9C2 cardiomyocytes via sodium-glucose cotransporter 1.
Chai Q; Meng Z; Lu D; Zhang Z; Liu M; Wu W
Mol Cell Biochem; 2021 Jun; 476(6):2479-2489. PubMed ID: 33608832
[TBL] [Abstract][Full Text] [Related]
5. Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts.
Meng L; Uzui H; Guo H; Tada H
Mol Med Rep; 2018 May; 17(5):6887-6892. PubMed ID: 29512713
[TBL] [Abstract][Full Text] [Related]
6. Improved glycemic control in mice lacking Sglt1 and Sglt2.
Powell DR; DaCosta CM; Gay J; Ding ZM; Smith M; Greer J; Doree D; Jeter-Jones S; Mseeh F; Rodriguez LA; Harris A; Buhring L; Platt KA; Vogel P; Brommage R; Shadoan MK; Sands AT; Zambrowicz B
Am J Physiol Endocrinol Metab; 2013 Jan; 304(2):E117-30. PubMed ID: 23149623
[TBL] [Abstract][Full Text] [Related]
7. Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents.
Oguma T; Nakayama K; Kuriyama C; Matsushita Y; Yoshida K; Hikida K; Obokata N; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Shiotani M
J Pharmacol Exp Ther; 2015 Sep; 354(3):279-89. PubMed ID: 26105952
[TBL] [Abstract][Full Text] [Related]
8. [Roles of Sodium-Glucose Cotransporter 1 (SGLT1) in the Induction of Cardiac Remodeling].
Hirose M; Matsushita N; Ishida N; Ibi M; Saito M
Yakugaku Zasshi; 2018; 138(7):939-943. PubMed ID: 29962473
[TBL] [Abstract][Full Text] [Related]
9. New insight in understanding the contribution of SGLT1 in cardiac glucose uptake: evidence for a truncated form in mice and humans.
Ferté L; Marino A; Battault S; Bultot L; Van Steenbergen A; Bol A; Cumps J; Ginion A; Koepsell H; Dumoutier L; Hue L; Horman S; Bertrand L; Beauloye C
Am J Physiol Heart Circ Physiol; 2021 Feb; 320(2):H838-H853. PubMed ID: 33416451
[TBL] [Abstract][Full Text] [Related]
10. Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice.
Ramratnam M; Sharma RK; D'Auria S; Lee SJ; Wang D; Huang XY; Ahmad F
J Am Heart Assoc; 2014 Aug; 3(4):. PubMed ID: 25092788
[TBL] [Abstract][Full Text] [Related]
11. Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.
Song P; Onishi A; Koepsell H; Vallon V
Expert Opin Ther Targets; 2016 Sep; 20(9):1109-25. PubMed ID: 26998950
[TBL] [Abstract][Full Text] [Related]
12. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.
Powell DR; Smith M; Greer J; Harris A; Zhao S; DaCosta C; Mseeh F; Shadoan MK; Sands A; Zambrowicz B; Ding ZM
J Pharmacol Exp Ther; 2013 May; 345(2):250-9. PubMed ID: 23487174
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of SGLT1 prevents the apoptosis of cardiomyocytes induced by glucose fluctuation via relieving oxidative stress and mitochondrial dysfunction.
Chai Q; Miao J; Liu M; Zhang Z; Meng Z; Wu W
Biochem Cell Biol; 2021 Jun; 99(3):356-363. PubMed ID: 33259229
[TBL] [Abstract][Full Text] [Related]
14. Effects of SGLT2 Inhibitors beyond Glycemic Control-Focus on Myocardial SGLT1.
Sayour AA; Ruppert M; Oláh A; Benke K; Barta BA; Zsáry E; Merkely B; Radovits T
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576016
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor 21 improves glucose homeostasis partially via down-regulation of Na
Wang N; Li S; Guo XC; Li JY; Ren GP; Li DS
Biomed Pharmacother; 2019 Jan; 109():1070-1077. PubMed ID: 30551357
[TBL] [Abstract][Full Text] [Related]
16. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states.
Banerjee SK; McGaffin KR; Pastor-Soler NM; Ahmad F
Cardiovasc Res; 2009 Oct; 84(1):111-8. PubMed ID: 19509029
[TBL] [Abstract][Full Text] [Related]
17. Replacement of Lost Substance P Reduces Fibrosis in the Diabetic Heart by Preventing Adverse Fibroblast and Macrophage Phenotype Changes.
Widiapradja A; Kasparian AO; McCaffrey SL; Kolb LL; Imig JD; Lacey JL; Melendez GC; Levick SP
Cells; 2021 Oct; 10(10):. PubMed ID: 34685639
[TBL] [Abstract][Full Text] [Related]
18. Knockout of Na
Song P; Huang W; Onishi A; Patel R; Kim YC; van Ginkel C; Fu Y; Freeman B; Koepsell H; Thomson S; Liu R; Vallon V
Am J Physiol Renal Physiol; 2019 Jul; 317(1):F207-F217. PubMed ID: 31091127
[TBL] [Abstract][Full Text] [Related]
19. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
[TBL] [Abstract][Full Text] [Related]
20. Potent Sodium/Glucose Cotransporter SGLT1/2 Dual Inhibition Improves Glycemic Control Without Marked Gastrointestinal Adaptation or Colonic Microbiota Changes in Rodents.
Du F; Hinke SA; Cavanaugh C; Polidori D; Wallace N; Kirchner T; Jennis M; Lang W; Kuo GH; Gaul MD; Lenhard J; Demarest K; Ajami NJ; Liang Y; Hornby PJ
J Pharmacol Exp Ther; 2018 Jun; 365(3):676-687. PubMed ID: 29674332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
